Edwards Lifesciences (NYSE:EW) VP Daniel Lippis Sells 619 Shares of Stock

Posted by Brian Himes on Sep 12th, 2026

Edwards Lifesciences Corporation (NYSE:EW – Get Free Report) VP Daniel Lippis sold 619 shares of the business’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $87.51, for a total value of $54,168.69. Following the completion of the sale, the vice president directly owned 40,034 shares of the company’s stock, valued at $3,503,375.34. The trade was a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Trading Down 2.6%

NYSE:EW opened at $84.54 on Friday. The stock’s 50 day moving average price is $89.16 and its 200 day moving average price is $85.79. The company has a market capitalization of $48.68 billion, a PE ratio of 48.59, a P/E/G ratio of 2.28 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29.

Edwards Lifesciences (NYSE:EW – Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm’s revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Key Stories Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

Positive Sentiment: CMS expands TAVR coverage: The Centers for Medicare and Medicaid Services will extend Medicare coverage to certain patients with severe aortic stenosis who do not yet have symptoms. The broader eligible patient population could increase demand for Edwards’ TAVR valves and procedures, a particularly important growth opportunity for the company. CMS expands TAVR Medicare coverage to asymptomatic patients
Positive Sentiment: Company welcomes the policy: Edwards said the national coverage determination should improve patient access to TAVR while reinforcing the role of multidisciplinary Heart Teams. The company also reaffirmed its 2026 financial guidance following the decision, suggesting no immediate deterioration in its outlook. Edwards Lifesciences Reaffirms 2026 Guidance Following Medicare TAVR Decision
Positive Sentiment: Analysts remain bullish: Citi initiated or reiterated a Buy view, while BTIG reaffirmed its Buy rating with a $110 price target. William Blair also maintained a Buy rating, citing the expanded TAVR coverage and inclusion of asymptomatic patients. These targets imply substantial potential upside from recent trading levels. Analyst Buy Rating on Edwards Lifesciences
Neutral Sentiment: Why the stock may still be under pressure: The reports identify no new company-specific negative catalyst. Investors may be waiting for evidence that the CMS change translates into procedure volumes and revenue, while Edwards’ relatively elevated valuation—about 49 times earnings—could make the shares sensitive to profit-taking or broader market weakness.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of recent research reports. Truist Financial increased their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. JPMorgan Chase & Co. upped their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Friday, July 24th. UBS Group initiated coverage on shares of Edwards Lifesciences in a research note on Tuesday, July 28th. They set a “buy” rating and a $110.00 target price for the company. Wall Street Zen raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Citigroup boosted their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $100.27.

Check Out Our Latest Stock Report on Edwards Lifesciences

Hedge Funds Weigh In On Edwards Lifesciences

A number of large investors have recently bought and sold shares of the company. Tidal Investments LLC boosted its holdings in shares of Edwards Lifesciences by 2.1% in the second quarter. Tidal Investments LLC now owns 104,368 shares of the medical research company’s stock valued at $9,441,000 after acquiring an additional 2,159 shares in the last quarter. Van Hulzen Asset Management LLC increased its stake in shares of Edwards Lifesciences by 4.3% during the second quarter. Van Hulzen Asset Management LLC now owns 35,500 shares of the medical research company’s stock worth $3,211,000 after acquiring an additional 1,476 shares during the period. National Pension Service increased its stake in shares of Edwards Lifesciences by 0.7% during the second quarter. National Pension Service now owns 998,775 shares of the medical research company’s stock worth $90,349,000 after acquiring an additional 7,009 shares during the period. Cidel Asset Management Inc. purchased a new position in Edwards Lifesciences during the second quarter worth about $227,000. Finally, Plimoth Trust Co. LLC purchased a new position in Edwards Lifesciences during the second quarter worth about $206,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

(Get Free Report)

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company’s portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.